Merck Now Owns Imago’s Oncology Platform Portfolio…

We first mentioned this oncology pipeline enhancing transaction about three months ago.

Merck has now completed the tender offer, with nearly 90 per cent of all Imago shares having been purchased for cash, and thus redeemed, and Imago has been delisted from the NASDAQ and SEC as of yesterday's close.

Another one in the books:

. . . Merck. . . today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 10, 2023, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago’s outstanding shares on a fully diluted basis.

All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for such shares. . . .

Now you know -- out, grinning. Ever, grinning.

नमस्ते